ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2019
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†.
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04570410 (Trials of Primary Excision Combined With Preoperative Neoadjuvant Therapy and Adjuvant Therapy Was Used as a First-line Comprehensive Therapy for Oligometastasis of Urothelial Carcinoma（UC）.), which is not on this map. Cited by 37 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 4 pooled it
25.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Trials of Primary Excision Combined With Preoperative Neoadjuvant Therapy and Adjuvant Therapy Was Used as a First-line Comprehensive Therapy for Oligometastasis of Urothelial Carcinoma（UC）.
Who cites it
37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 180 citations in OpenAlex.
- Prognostic value of preoperative systemic immune-inflammation index in patients with bladder cancer undergoing radical cystectomy: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Efficacy of Metastasectomy for Metastatic Bladder Cancer: A Systematic Review and Meta-Analysis.International journal of urology : official journal of the Japanese Urological Association · 2025Pooled it
- Criteria and indicators to evaluate quality of care in genitourinary tumour boards.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Pooled it
- Oncological effectiveness of bladder-preserving trimodal therapy versus radical cystectomy for the treatment of muscle-invasive bladder cancer: a system review and meta-analysis.World journal of surgical oncology · 2023Pooled it
- The DEpth of Endoscopic Perforation scale to assess intraoperative perforations during transurethral resection of bladder tumor: subgroup analysis of a randomized controlled trial.World journal of urology · 2023Trial
- A comparative analysis of variant histology and urothelial bladder cancer following radical cystectomy.International urology and nephrology · 2026Article
- Asia-Pacific collaborative consensus statements on water vapor thermal therapy (Rezūm) incorporating a systematic review, a two-round Delphi survey, and a consensus meeting.Prostate international · 2026Article
- ASO Practice Guidelines Series: Surgical Management of Bladder Cancer Relapse.Annals of surgical oncology · 2026Review
- Navigating Therapeutic Landscapes in Urothelial Cancer: From Chemotherapy to Precision Immuno-Oncology.Cancers · 2025Review
- Sphingolipid Metabolism Dysregulation Drives Immune Microenvironment Remodeling and Predicts Prognosis in Bladder Cancer.International journal of genomics · 2025Article
- Distant recurrence of non-muscle invasive bladder cancer 8 years after initial treatment.IJU case reports · 2024Article
- The Role of Maximal TURBT in Muscle-Invasive Bladder Cancer: Balancing Benefits in Bladder Preservation and Beyond.Cancers · 2024Review
- Prognostic Value of Postneoadjuvant Chemotherapy Neutrophil-to-Lymphocyte Ratio in Patients undergoing Radical Cystectomy.Journal of clinical medicine · 2024Article
- Molecular classification of muscle-invasive bladder cancer based on a simplified immunohistochemical panel using GATA3, CK5/6 and p16.Biomolecules & biomedicine · 2023Article
- Article
- Defining Oligometastatic Bladder Cancer: A Systematic Review.European urology open science · 2023Review
- Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study.HemaSphere · 2023Article
- Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis.Current oncology (Toronto, Ont.) · 2022Article
- TUXEDO: A phase I/II trial of cetuximab with chemoradiotherapy in muscle-invasive bladder cancer.BJU international · 2022Article
- Distant metastasis without regional progression in non-muscle invasive bladder cancer: case report and pooled analysis of literature.World journal of surgical oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
121 authors at 20 institutions in 23 countries.
A HorwichEmeritus Professor, The Institute of Cancer Research, London, UK; Emeritus Professor, The Institute of Cancer Research, London, UK. Electronic address: clinicalguidelines@esmo.org.
M BabjukDepatment of Urology, 2nd Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic; Department of Urology, Medical University of Vienna, Vienna, Austria.
J BellmuntIMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain; Harvard Medical School, Boston, USA.
H M BruinsDepartment of Urology, Radboud University Medical Center, Nijmegen.
T M De ReijkeDepartment of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
M De SantisDepartment of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Charité University Hospital, Berlin, Germany.
S GillessenDivision of Cancer Sciences, University of Manchester, Manchester; The Christie NHS Foundation Trust, Manchester, UK; Division of Oncology and Haematology, Kantonsspital St Gallen, St Gallen; University of Bern, Bern, Switzerland.
N JamesUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham.
S MaclennanAcademic Urology Unit, University of Aberdeen, Aberdeen, UK.
J PalouDepartment of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
T PowlesThe Royal Free NHS Trust, London; Barts Cancer Institute, Queen Mary University of London, London, UK.
M J RibalUro-Oncology Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain.
S F ShariatDepatment of Urology, 2nd Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic; Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York; Department of Urology, University of Texas Southwestern Medical Center, Dallas, USA; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
T Van Der KwastDepartment of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands.
E XylinasDepartment of Urology, Bichat-Claude Bernard Hospital, Assistance Publique Hôpitaux de Paris, Paris; Paris Descartes University, Paris, France.
N AgarwalHuntsman Cancer Institute, University of Utah (NCI-CCC), Salt Lake City, USA.
T ArendsUrology Department, Canisius-Wilhelmina Ziekenhuis Nijmegen, Nijmegen, The Netherlands.
A Bamias2nd Propaedeutic Dept of Internal Medicine, Medical School, National & Kapodistrian University of Athens, Athens, Greece.
A BirtleDivision of Cancer Sciences, University of Manchester, Manchester; Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston, UK.
P C BlackDepartment of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.
B H BochnerDepartment of Urology, Weill Cornell Medical College, New York; Urology Service, Department of Urology, Memorial Sloan Kettering Cancer Center, New York, USA.
M BollaEmeritus Professor of Radiation Oncology, Grenoble - Alpes University, Grenoble, France.
J L BoormansDepartment of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands.
A BossiDepartment of Radiation Oncology, Gustave Roussy Institute, Villejuif, France.
A BrigantiDepartment of Urology, Urological Research Institute, Milan; Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy.
I BrummelhuisDepartment of Urology, Radboud University Medical Center, Nijmegen.
M BurgerDepartment of Urology, Caritas-St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
D CastellanoMedical Oncology Department, 12 de Octubre University Hospital (CIBERONC), Madrid, Spain.
R CathomasDepartment Innere Medizin, Abteilung Onkologie und Hämatologie, Kantonsspital Graubünden, Chur, Switzerland.
A ChitiDepartment of Biomedical Sciences, Humanitas University, Milan; Humanitas Research Hospital, Milan, Italy.
A ChoudhuryDivision of Cancer Sciences, University of Manchester, Manchester; The Christie NHS Foundation Trust, Manchester, UK.
E CompératDepartment of Pathology, Tenon Hospital, HUEP, Paris; Sorbonne University, Paris, France.
S CrabbCancer Sciences Unit, University of Southampton, Southampton, UK.
S CulineDepartment of Cancer Medicine, Hôpital Saint Louis, Paris.
B De BariRadiation Oncology Department, Centre Hospitalier Régional Universitaire "Jean Minjoz" of Besançon, INSERM UMR 1098, Besançon, France; Radiation Oncology Department, Centre Hospitalier Universitaire Vaudois, Université de Lausanne, Lausanne, Switzerland.
W DeBlokDepartment of Urology, University Medical Center Utrecht, Utrecht, The Netherlands.
P J L De VisschereDepartment of Radiology and Nuclear Medicine, Division of Genitourinary Radiology and Mammography, Ghent University Hospital, Ghent.
K DecaesteckerDepartment of Urology, Ghent University Hospital, Ghent, Belgium.
K DimitropoulosDepartment of Urology, Aberdeen Royal Infirmary, Aberdeen, UK.
J L Dominguez-EscrigServicio de Urología, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
S FantiDepartment of Nuclear Medicine, Policlinico S Orsola, University of Bologna, Bologna, Italy.
V FonteyneDepartment of Radiotherapy Oncology, Ghent University Hospital, Ghent, Belgium.
M FrydenbergDepartment of Surgery, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia.
J J FuttererDepartment of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
G GakisDepartment of Urology and Paediatric Urology, University Hospital of Würzburg, Julius-Maximillians University, Würzburg, Germany.
B GeavleteDepartment of Urology, Saint John Emergency Clinical Hospital, Bucharest, Romania.
P GonteroDivision of Urology, Molinette Hospital, University of Studies of Torino, Torino, Italy.
B GrubmüllerDepartment of Urology, Medical University of Vienna, Vienna, Austria.
S HafeezDivision of Radiotherapy and Imaging, The Institute of Cancer Research, London; Department of Clinical Oncology, The Royal Marsden NHS Foundation Trust, London, UK.
D E HanselDepartment of Urology, University of California, San Diego Pathology, La Jolla, USA.
A HartmannInstitute of Pathology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Erlangen, Germany.
D HayneDepartment of Urology, UWA Medical School, University of Western Australia, Perth, Australia.
A M HenryLeeds Institute of Medical Research, University of Leeds, Leeds, UK.
V HernandezDepartment of Urology, Hospital Universitario Fundación de Alcorcón, Madrid, Spain.
H HerrUrology Service, Department of Urology, Memorial Sloan Kettering Cancer Center, New York, USA.
K HerrmannDepartment of Nuclear Medicine, Universitätsklinikum Essen, Essen, Germany.
P HoskinDivision of Cancer Sciences, University of Manchester, Manchester; The Christie NHS Foundation Trust, Manchester, UK; Mount Vernon Centre for Cancer Treatment, London, UK.
J HuguetDepartment of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
B A Jereczek-FossaDepartment of Oncology and Hemato-oncology, University of Milan, Milan; Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milan, Italy.
R JonesInstitute of Cancer Sciences, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
A M KamatDepartment of Urology - Division of Surgery, The University of Texas, MD Anderson Cancer Center, Houston, USA.
V KhooDivision of Radiotherapy and Imaging, The Institute of Cancer Research, London; Department of Clinical Oncology, The Royal Marsden NHS Foundation Trust, London, UK; Department of Medicine, University of Melbourne, Melbourne; Monash University, Melbourne, Australia.
A E KiltieCRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.
S KregeDepartment of Urology, Pediatric Urology and Urologic Oncology, Kliniken Essen-Mitte, Essen, Germany.
S LadoireDepartment of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
P C LaraDepartment of Oncology, Hospital Universitario San Roque, Canarias; Universidad Fernando Pessoa, Canarias, Spain.
A LeliveldDepartment of Urology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
E Linares-EspinósDepartment of Urology, University Hospital La Paz, Madrid, Spain.
V LøgagerDepartment of Radiology, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark.
A LorchDepartment of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.
Y LoriotDépartement de Médecine Oncologique, Gustave Roussy, INSERM U981, Université Paris-Sud, Université Paris-Saclay, Villejuif, France.
R MeijerUMC Utrecht Cancer Center, MS Oncologic Urology, Utrecht, The Netherlands.
M Carmen MirServicio de Urología, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
M MoschiniDepartment of Urology, Luzerner Kantonsspital, Luzern, Switzerland.
H MostafidDepartment of Urology, Royal Surrey County Hospital, Guildford, UK.
A-C MüllerDepartment of Radiation Oncology, Eberhard Karls University, Tübingen, Germany.
C R MüllerCancer Treatment Centre, Sorlandet Hospital, Kristiansand, Norway.
J N'DowAcademic Urology Unit, University of Aberdeen, Aberdeen, UK; Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK.
A NecchiDepartment of Medical Oncology, Istituto Nazionale Tumori of Milan, Milan, Italy.
Y NeuzilletDepartment of Urology, Hospital Foch, University of Versailles-Saint-Quentin-en-Yvelines, Suresnes, France.
J R OddensDepartment of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
J OldenburgDepartment of Oncology, Akershus University Hospital, Lørenskog; Faculty of Medicine, University of Oslo, Oslo, Norway.
S OsantoDepartment of Clinical Oncology, Leiden University Medical Center, Leiden.
W J G OyenDepartment of Biomedical Sciences, Humanitas University, Milan; Humanitas Research Hospital, Milan, Italy; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, The Netherlands.
L Pacheco-FigueiredoDepartment of Urology, Centro Hospitalar São João, Porto; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.
H PappotDepartment of Oncology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark.
M I PatelDepartment of Urology, Westmead Hospital, University of Sydney, Sydney, Australia.
B R PietersDepartment of Radiation Oncology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam.
K PlassEAU Guidelines Office, Arnhem, The Netherlands.
M RemziDepartment of Urology, Medical University of Vienna, Vienna, Austria.
M RetzDepartment of Urology, Rechts der Isar Medical Center, Technical University of Munich, Munich, Germany.
J RichenbergDepartment of Imaging and Nuclear Medicine, Royal Sussex County Hospital, Brighton; Brighton and Sussex Medical School, Brighton, UK.
M RinkDepartment of Urology, University Medical Center Hamburg-Eppendorf, Hamburg.
F RoghmannDepartment of Urology, Ruhr-University Bochum, Marien Hospital, Herne, Germany.
J E RosenbergDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York; Weill Cornell Medical College, New York, USA.
M RouprêtDepartment of Urology, Sorbonne Université, GRC n°5, ONCOTYPE-URO, AP-HP, Hôpital Pitié-Salpêtrière, Paris.
O RouvièreHospices Civils de Lyon, Service d'Imagerie Urinaire et Vasculaire, Hôpital Edouard Herriot, Lyon; Université de Lyon, Université Lyon 1, Faculté de Médecine Lyon Est, Lyon, France.
C SalembierDepartment of Radiation Oncology, Europe Hospitals Brussels, Brussels, Belgium.
A SalminenDepartment of Urology, University Hospital of Turku, Turku, Finland.
P SargosDepartment of Radiotherapy, Institut Bergonié, Bordeaux, France.
S SenguptaDepartment of Surgery, Austin Health, University of Melbourne, Melbourne; Eastern Health Clinical School, Monash University, Melbourne, Australia.
A SherifDepartment of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
R J SmeenkDepartment of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
A SmitsDepartment of Urology, Radboud University Medical Center, Nijmegen.
A StenzlDepartment of Urology, Eberhard Karls University Tübingen, Tübingen, Germany.
G N ThalmannDepartment of Urology, Inselspital, Bern University Hospital, Berne, Switzerland.
B TombalDivision of Urology, IREC, Cliniques Universitaires Saint Luc, UCL, Brussels, Belgium.
B TurkbeyMolecular Imaging Program, National Cancer Institute, Bethesda, USA.
S Vahr LauridsenDepartment of Urology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
R ValdagniDepartment of Oncology and Hemato-oncology, Università degli Studi di Milano, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
A G Van Der HeijdenDepartment of Urology, Radboud University Medical Center, Nijmegen.
H Van PoppelDepartment of Urology, University Hospitals Leuven, Leuven, Belgium.
M D VartolomeiDepartment of Urology, Medical University of Vienna, Vienna, Austria; Department of Cell and Molecular Biology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Targu Mures, Romania.
E VeskimäeDepartment of Urology, Tampere University Hospital, Tampere, Finland.
A VilasecaUro-Oncology Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain.
F A Vives RiveraClinica HematoOncologica Bonadona Prevenir, Universidad Metropolitana, Clinica Club de Leones, Barranquilla, Colombia.
T WiegelDepartment of Radiation Oncology, University Hospital Ulm, Ulm, Germany.
P WiklundIcahn School of Medicine, Mount Sinai Health System, New York City, USA; Department of Urology, Karolinska Institutet, Stockholm, Sweden.
A WilliamsDepartment of Urology, Auckland City Hospital, Auckland, New Zealand.
R ZigeunerDepartment of Urology, Medizinische Universität Graz, Graz, Austria.
J A WitjesDepartment of Urology, Radboud University Medical Center, Nijmegen.
Radboud University Nijmegen · NLAmsterdam University Medical Centers · NLGhent University Hospital · BEMedical University of Vienna · ATMemorial Sloan Kettering Cancer Center · USErasmus MC · NLFundación Instituto Valenciano de Oncología · ESHumanitas University · ITRoyal Marsden NHS Foundation Trust · GBSorbonne Université · FRUniversitat Autònoma de Barcelona · ESUniversitat de Barcelona · ESUniversité Claude Bernard Lyon 1 · FRUniversity Medical Center Utrecht · NLUniversity of Aberdeen · GBUniversity of Manchester · GBUniversity of Milan · ITUniversity of Tübingen · DEAberdeen Royal Infirmary · GBAuckland City Hospital · NZ
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial.
objectiveTo bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management.
designA steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference.
settingOnline Delphi survey and consensus conference.
participantsThe European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease.
conclusionsThese consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach.
Indexed as
ConsensusPractice Guidelines as TopicDelphi TechniqueEuropeHumansInternational CooperationMedical OncologyNeoplasm StagingSocieties, MedicalStakeholder ParticipationSurveys and QuestionnairesUrinary BladderUrinary Bladder NeoplasmsUrologybladder cancerconsensusDelphidiagnosisfollow-uptreatment
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT04570410ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.